These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26748742)

  • 21. Calibration of the WHO 5th IS for Blood Coagulation Factor IX, Concentrate and Ph. Eur. Human Coagulation Factor IX Concentrate Biological Reference Preparation Batch 3 and investigation of the suitability of an IS as potency standard for purified full-length recombinant FIX.
    Gray E; Hogwood J; Dougall T; Rigsby P; Matejtschuk P; Terao E
    Pharmeur Bio Sci Notes; 2021; 2021():26-68. PubMed ID: 33783349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise.
    Lowe A; Kitchen S; Jennings I; Kitchen DP; Woods TAL; Walker ID
    Haemophilia; 2020 Nov; 26(6):1087-1091. PubMed ID: 33094895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
    Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
    Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A critical appraisal of one-stage and chromogenic assays of factor VIII activity.
    Peyvandi F; Oldenburg J; Friedman KD
    J Thromb Haemost; 2016 Feb; 14(2):248-61. PubMed ID: 26663865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
    Müller J; Goldmann G; Marquardt N; Pötzsch B; Oldenburg J
    Hamostaseologie; 2020 Nov; 40(S 01):S15-S20. PubMed ID: 33187006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.
    Hillarp A; Bowyer A; Ezban M; Persson P; Kitchen S
    Haemophilia; 2017 May; 23(3):458-465. PubMed ID: 28198071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues.
    Kitchen S; Kershaw G; Tiefenbacher S
    Haemophilia; 2016 Jul; 22 Suppl 5():72-7. PubMed ID: 27405680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B.
    Zwagemaker AF; Kloosterman FR; Gouw SC; Boyce S; Brons P; Cnossen MH; Collins PW; Eikenboom J; Hay C; Hengeveld RCC; Jackson S; Klopper-Tol CAM; Kruip MJHA; Gorkom BL; Male C; Nieuwenhuizen L; Shapiro S; Fijnvandraat K; Coppens M;
    J Thromb Haemost; 2023 Apr; 21(4):850-861. PubMed ID: 36696222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Considerations on activity assay discrepancies in factor VIII and factor IX products.
    Ovanesov MV; Jackson JW; Golding B; Lee TK
    J Thromb Haemost; 2021 Sep; 19(9):2102-2111. PubMed ID: 34145730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring of modified factor VIII and IX products.
    Kitchen S; Gray E; Mertens K
    Haemophilia; 2014 May; 20 Suppl 4():36-42. PubMed ID: 24762273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B.
    Abraham S; Duncan EM
    Methods Mol Biol; 2023; 2663():569-588. PubMed ID: 37204737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B.
    Adcock DM; Strandberg K; Shima M; Marlar RA
    Int J Lab Hematol; 2018 Dec; 40(6):621-629. PubMed ID: 29979821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cost-effective approach to factor assay calibration using a truncated live calibration curve.
    Guy S; Sermon-Cadd AM; Shepherd FM; Kitchen S; Bowyer AE
    Int J Lab Hematol; 2019 Oct; 41(5):679-683. PubMed ID: 31421012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products.
    Ovanesov MV; Williams SC; Nübling CM; Dodt J; Hilger A; Maryuningsih Y; Gray E
    Biologicals; 2020 Sep; 67():88-93. PubMed ID: 32847723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia
    Ezban M; Hermit MB; Persson E
    Haemophilia; 2019 Jan; 25(1):154-161. PubMed ID: 30664825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-stage vs. chromogenic assays in haemophilia A.
    Potgieter JJ; Damgaard M; Hillarp A
    Eur J Haematol; 2015 Feb; 94 Suppl 77():38-44. PubMed ID: 25560793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays.
    Peyvandi F; Kenet G; Pekrul I; Pruthi RK; Ramge P; Spannagl M
    J Thromb Haemost; 2020 Jun; 18(6):1242-1255. PubMed ID: 32115865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
    Sommer JM; Sadeghi-Khomami A; Barnowski C; Wikén M; Willemze AJ
    Int J Lab Hematol; 2020 Jun; 42(3):350-358. PubMed ID: 32202380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
    Wilmot HV; Hogwood J; Gray E
    Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.